Search hospitals > Illinois > Danville
Carle on Vermilion
Claim this profileDanville, Illinois 61832
Global Leader in Lung Cancer
Global Leader in Breast Cancer
Conducts research for Cancer
Conducts research for Breast cancer
Conducts research for Non-Small Cell Lung Cancer
286 reported clinical trials
14 medical researchers
Summary
Carle on Vermilion is a medical facility located in Danville, Illinois. This center is recognized for care of Lung Cancer, Breast Cancer, Cancer, Breast cancer, Non-Small Cell Lung Cancer and other specialties. Carle on Vermilion is involved with conducting 286 clinical trials across 426 conditions. There are 14 research doctors associated with this hospital, such as Suparna Mantha, Vamsi K. Vasireddy, Maria T. Grosse-Perdekamp, and Kendrith Rowland, MD.Area of expertise
1Lung Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderStage IV
HER2 negative
ER positive
Top PIs
Suparna ManthaCarle Cancer Center6 years of reported clinical research
Studies Colorectal Cancer
Studies Colon Cancer
35 reported clinical trials
78 drugs studied
Vamsi K. VasireddyCarle Cancer Center3 years of reported clinical research
Expert in Cancer
Studies Lung Cancer
30 reported clinical trials
54 drugs studied
Maria T. Grosse-PerdekampCarle Cancer Center3 years of reported clinical research
Expert in Breast Cancer
Studies Breast cancer
31 reported clinical trials
62 drugs studied
Kendrith Rowland, MDCarle Cancer Center8 years of reported clinical research
Studies Breast Cancer
Studies Cancer
30 reported clinical trials
61 drugs studied
Clinical Trials running at Carle on Vermilion
Lung Cancer
Bladder Cancer
Prostate Cancer
Melanoma
Cancer
Kidney Cancer
Ovarian Cancer
Breast Cancer
Cutaneous Melanoma
Pancreatic Cancer
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Stereotactic Radiosurgery vs Whole-Brain Radiotherapy
for Brain Metastasis from Lung Cancer
This phase III trial compares the effect of stereotactic radiosurgery to standard of care memantine and whole brain radiation therapy that avoids the hippocampus (the memory zone of the brain) for the treatment of small cell lung cancer that has spread to the brain. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue. Whole brain radiation therapy delivers a low dose of radiation to the entire brain including the normal brain tissue. Hippocampal avoidance during whole-brain radiation therapy (HA-WBRT) decreases the amount of radiation that is delivered to the hippocampus which is a brain structure that is important for memory. The drug, memantine, is also often given with whole brain radiotherapy because it may decrease the risk of side effects related to thinking and memory. Stereotactic radiosurgery may decrease side effects related to memory and thinking compared to standard of care HA-WBRT plus memantine.
Recruiting2 awards Phase 315 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Carle on Vermilion?
Carle on Vermilion is a medical facility located in Danville, Illinois. This center is recognized for care of Lung Cancer, Breast Cancer, Cancer, Breast cancer, Non-Small Cell Lung Cancer and other specialties. Carle on Vermilion is involved with conducting 286 clinical trials across 426 conditions. There are 14 research doctors associated with this hospital, such as Suparna Mantha, Vamsi K. Vasireddy, Maria T. Grosse-Perdekamp, and Kendrith Rowland, MD.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.